Nov 29 2016

Medimmune and Abpro Enter into A Collaborative Agreement For a Novel Bispecific Antibody

MedImmune, the global biologics research and development arm of AstraZeneca, and Abpro, an integrated life sciences company at the forefront of synthetic biology, today announced they have entered into a collaborative agreement to advance the development of a preclinical, novel bispecific antibody targeting angiopoietin-2 and vascular endothelial growth factor (Ang2-VEGF).

Read more →

Press Releases


Mar 21 2017

Abpro Expands Senior Leadership Team and Announces Appointment of Gavin MacBeath, Ph.D. as Chief Scientific Officer

WOBURN, Mass., March 21, 2017 – Abpro, a therapeutic antibody company targeting human disease and at the forefront of synthetic biology, today announced the expansion of its senior leadership team with the hiring of Dr. Gavin MacBeath, Ph.D. as Chief Scientific Officer. Dr. MacBeath brings over 16 years of experience in academia and the biotechnology industry, with expertise in systems biology, drug discovery, translational research, companion diagnostics, and clinical development of early-stage programs. He will report directly to Ian Chan, Chairman and Chief Executive Officer of Abpro.

Read More →

Feb 2 2017

Abpro Expands Senior Leadership Team and Announces Adam Mostafa as Chief Financial Officer

WOBURN, Mass., February 01, 2017 – Abpro, a leading therapeutic antibody company targeting human disease and at the forefront of synthetic biology, today announced the expansion of its senior leadership team with Adam Mostafa as Chief Financial Officer

Read More →

Nov 29 2016

Medimmune and Abpro Enter into A Collaborative Agreement For a Novel Bispecific Antibody

MedImmune, the global biologics research and development arm of AstraZeneca, and Abpro, an integrated life sciences company at the forefront of synthetic biology, today announced they have entered into a collaborative agreement to advance the development of a preclinical, novel bispecific antibody targeting angiopoietin-2 and vascular endothelial growth factor (Ang2-VEGF).

Read More →

May 20 2016

Abpro Announces Agreements with Two Boston Hospitals

Abpro, an integrated life science company at the forefront of synthetic biology, today announced co-development agreements with Massachusetts General Hospital (MGH) and Brigham and Women’s Hospital (BWH), two of the country’s leading academic medical centers

Read More →

Apr 25 2016

Abpro Announces Investment and Partnership with Essex Bio

Abpro, an integrated life science company at the forefront of synthetic biology, today announced a partnership with Essex Bio, a China-based biopharmaceutical company.

Read More →

Dec 16 2014

Abpro appoints Ron Levy M.D., to Scientific Advisory Board

Dr. Levy is widely known for his original work on Rituxan®, the first monoclonal antibody approved by the Food and Drug Administration for the treatment of cancer.

Read More →

Oct 10 2014

Abpro Co-Founder Eugene Chan Wins Nokia Sensing XChallenge

Chan led a team from DNA Medicine Institute (DMI), a Cambridge-based medical technology incubator and lab, that developed rHEALTH, a compact portable device that can run hundreds of clinical lab tests on a single drop of blood with gold standard accuracy.

Read More →

Abpro in the News


Nov 30 2016

MedImmune, Abpro to Develop Bispecific Antibody

MedImmune and Abpro said today they will partner to develop a preclinical, novel, bispecific antibody targeting angiopoietin-2 and vascular endothelial growth factor (Ang2-VEGF).

Read More →

Nov 30 2016

MedImmune and Abpro launch bispecific antibody spinout

Share Facebook Twitter LinkedIn Email Print AstraZeneca’s biologics arm MedImmune and synthetic biology co Abpro have joined forces on a new Ang2-VEGF research collab that will come together under a new spinout.

Read More →

Oct 13 2016

GEN Roundup: Immunoassays: Life Science Critical Tools

Nothing Beats Immunoassays for Sensitivity, Specificity, and Flexibility, but Users Want More and Vendors Are Delivering

Read More →

Sign up for updates: